A new approach to treating secondary pulmonary hypertension
OBJECTIVE: to study the clinical and hemodynamic effects and safety of the ACE inhibitor dirotone and AT1-receptor antagonist losartan in secondary pulmonary hypertension (PH) in patients with chronic obstructive bronchitis (COB).
SUBJECTS AND METHODS: The time course of changes in hemodynamic parameters and diurnal BP profile in 48 patients with COB concurrent with Functional Class (FC) III-IV secondary PH, receiving 4-week therapy including dirotone and losartan.
RESULTS: The inclusion of dirotone or losartan into the combined therapy of patients with secondary pulmonary hypertension resulted in alleviated PH, caused positive changes in the right cardiac cavities, and normalized diurnal BP variables. Therapy with dirotone was effective in COB patients with the clinical signs of FC III PH only during its course use, that with losartan was beneficial in FC III and IV PH. The long-term outpatient use of losartan in individually adjusted doses produced pronounced beneficial clinical effects and led to significantly improved hemodynamic parameters.
CONCLUSION: The ACE inhibitor dirotone and the AT1-receptor antagonist losartan may be recommended for the correction of hemodynamic disorders in secondary PH in patients with COB.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2005 |
|---|---|
| Enthalten in: |
Problemy tuberkuleza i boleznei legkikh - (2005), 9 vom: 01., Seite 33-6; discussion 36 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Butorov, I V [VerfasserIn] |
|---|
| Themen: |
Angiotensin-Converting Enzyme Inhibitors |
|---|
| Anmerkungen: |
Date Completed 15.12.2005 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM158857062 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM158857062 | ||
| 003 | DE-627 | ||
| 005 | 20231223083012.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n0530.xml |
| 035 | |a (DE-627)NLM158857062 | ||
| 035 | |a (NLM)16279515 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Butorov, I V |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A new approach to treating secondary pulmonary hypertension |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2005 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: to study the clinical and hemodynamic effects and safety of the ACE inhibitor dirotone and AT1-receptor antagonist losartan in secondary pulmonary hypertension (PH) in patients with chronic obstructive bronchitis (COB) | ||
| 520 | |a SUBJECTS AND METHODS: The time course of changes in hemodynamic parameters and diurnal BP profile in 48 patients with COB concurrent with Functional Class (FC) III-IV secondary PH, receiving 4-week therapy including dirotone and losartan | ||
| 520 | |a RESULTS: The inclusion of dirotone or losartan into the combined therapy of patients with secondary pulmonary hypertension resulted in alleviated PH, caused positive changes in the right cardiac cavities, and normalized diurnal BP variables. Therapy with dirotone was effective in COB patients with the clinical signs of FC III PH only during its course use, that with losartan was beneficial in FC III and IV PH. The long-term outpatient use of losartan in individually adjusted doses produced pronounced beneficial clinical effects and led to significantly improved hemodynamic parameters | ||
| 520 | |a CONCLUSION: The ACE inhibitor dirotone and the AT1-receptor antagonist losartan may be recommended for the correction of hemodynamic disorders in secondary PH in patients with COB | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Lisinopril |2 NLM | |
| 650 | 7 | |a E7199S1YWR |2 NLM | |
| 650 | 7 | |a Losartan |2 NLM | |
| 650 | 7 | |a JMS50MPO89 |2 NLM | |
| 700 | 1 | |a Verbitskiĭ, O N |e verfasserin |4 aut | |
| 700 | 1 | |a Butorov, S I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Problemy tuberkuleza i boleznei legkikh |d 2003 |g (2005), 9 vom: 01., Seite 33-6; discussion 36 |w (DE-627)NLM125402864 |x 1728-2993 |7 nnns |
| 773 | 1 | 8 | |g year:2005 |g number:9 |g day:01 |g pages:33-6; discussion 36 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2005 |e 9 |b 01 |h 33-6; discussion 36 | ||